摘要
目的:观察复方苦参注射液联合化疗对晚期肿瘤的近期疗效。方法:自2003年10月～2006年10月,42例晚期恶性肿瘤患者应用复方苦参注射液联合化疗,应用2个周期以上进行疗效评价。结果:入组患者PR40.5%,SD50%,PD9.5%,中位生存期13.1个月,1年生存期为41.7%。不良反应多为骨髓抑制,胃肠道反应多为Ⅰ、Ⅱ度。结论:复方苦碱注射液能够减少化疗毒副作用,增加患者化疗耐受性,提高生活质量。
OBJECTIVE： To observe the short - term efficacy of compound matrine combined chemotherapy for end - stage tumor. METHODS： Between Oct., 2003 and Oct., 2006, a total of 42 patients with advanced malignant tumor were assigned to receive compound matrine combined chemotherapy, with efficacy evaluated after medication for over 2 cycles. RESULTS： PR, SD, PD and 1 - year survival of the enrolled patients were 40.5%, 50%, 9.5% and 41.7%, respectively, with medium survival of 13.1 months. The major adverse events were myelosuppression, gastrointestinal tract reactions （Ⅰ and Ⅱ grade）. CONCLUSION： Compound matrine can reduce toxic effects of chemotherapy while enhancing patients＇ tolerance to chemotherapy and improving patients＇ quality of life.
出处
《中国医院用药评价与分析》
2007年第2期147-148,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
复方苦参注射液
化疗
恶性肿瘤
近期疗效
compound matrine injection
chemotherapy
malignant tumor
short- term efficacy
